Krystal Biotech (KRYS) Net Income towards Common Stockholders Growth (5y) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Krystal Biotech | 9.05 Bn | 8.23 Bn | 110.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.82% |
| Dec 31, 2025 | 47.37% |
| Sep 30, 2025 | 59.30% |
| Jun 30, 2025 | 50.09% |
| Mar 31, 2025 | 54.10% |
| Dec 31, 2024 | 60.03% |
| Sep 30, 2024 | 52.92% |
| Jun 30, 2024 | 37.48% |
| Mar 31, 2024 | 17.36% |
| Dec 31, 2023 | 34.15% |
| Sep 30, 2023 | 99.13% |
| Jun 30, 2023 | -70.93% |
| Mar 31, 2023 | -83.96% |
| Dec 31, 2022 | -87.23% |
| Sep 30, 2022 | -41.44% |
| Jun 30, 2022 | -105.93% |
| Mar 31, 2022 | -151.76% |
| Dec 31, 2021 | -103.36% |
| Sep 30, 2021 | -117.27% |